Kornimate/medical-research-clean huggingface dataset:
repeatability and reproducibility of skin test endpoint titration

Conditions: Allergic Reaction

Summary: this study will examine the within-tester repeatability and between-tester reproducibility of skin test endpoint titrations performed in those with allergic sensitivities.

participants will be recruited from the local community. participants with a previous history of skin prick testing in our lab will not be required to undergo preliminary skin prick testing, as the allergen to be used for skin prick titrations is known. new participants will undergo skin prick testing. the procedures for skin prick testing and skin test endpoint (ste) titration will be guided by the allergen cic allergen skin titration by epicutaneous method (prick) standard operating procedure. different allergen extracts for the skin prick test or different doubling doses of an allergen in duplicate for the ste will be applied to the forearm, pricked with a lancet, and assessed ten minutes later by measuring the wheal sizes produced. the study will require three visits to the lab (i.e. three testers), each separated by one week and lasting roughly 30 minutes. each visit will entail the duplicate ste procedure performed by a different tester. if a participant is new to the lab, they will undergo skin prick testing during their first lab visit prior to undergoing the skin prick titration and so, their first study visit may last up to one hour.

Eligibility criteria:
inclusion criteria: * must have allergic sensitivities confirmed by a skin prick test (or historically) to at least one of the study allergens exclusion criteria: * skin condition on the forearms * if there is a situation where interpretation of skin reactions would be difficult (e.g. sleeve tattoos, scarring) * regular use of anti-histamines (assessed on a case-by-case basis)

Keywords: skin test endpoint
seriacl™ device trial for anterior cruciate ligament (acl) reconstruction

Conditions: Anterior Cruciate Ligament; Knee Injuries

Summary: the seriacl device was developed as an alternative to an autograft (i.e., tissue that is taken from a patient's own body) or an allograft (i.e., tissue that is taken from a cadaver) for acl reconstruction. the seriacl device is made of silk yarns, knit and processed with sericoat™ surface treatment which makes it easier to wet the material. the seriacl device is designed to be a temporary support structure to replace the torn acl and to stabilize the knee joint following surgical repair. it is designed to use the body's own healing process to regenerate the patient's own new ligament tissue. as the new tissue grows and the support structure is needed less over time, the seriacl device is bioresorbed (i.e., broken down) by the patient's body. the seriacl device is designed to be installed with standard surgical techniques for acl repair. this study is designed to test the safety of the seriacl device in primary total acl repair in patients with a torn acl. the study will evaluate whether repair of the acl with the seriacl device will return the knee to normal function and what, if any, side effects will occur.


Eligibility criteria:
inclusion criteria: * complete acl rupture * injured knee range of motion \>= 75% of contralateral knee * mcl tear grading \<= 2 * sign informed consent. exclusion criteria: * prior acl reconstruction * complete pcl tear * locked bucket handle tear or complex tears of the menisci. * contralateral knee ligament injury * known joint disease * known allergy to silk * active drug or alcohol abuse * pregnant

Keywords: acl ligament acl injury
evaluation of diabetes care at austrian gps

Conditions: Type 2 Diabetes

Summary: this registery should show the medical care of patient with type 2 diabetes (t2d) at gp-offices. furthermore data of co morbidities and risk factors should be evaluated. objectives of this nis (cross-sectional study) are: * to evaluate which characteristics or co-morbidities are being existent for patient with t2d at gp level, * to evaluate representative profile of patient with t2d in austria, * to evaluate which medical therapies are used.


Eligibility criteria:
inclusion criteria: * diabetes mellitus type ii exclusion criteria: * diabetes mellitus type i * gestation diabetes * induced diabetes

Keywords: diabetes care at gps in austria characteristic of diabetes patients at gps in austria
elucidate outcomes of elective high-grade/total occlusion intracranial arteries using low-profile self-expanding stent

Conditions: Intracranial Atherosclerosis; Stent Stenosis; Ischemic Stroke

Summary: intracranial atherosclerotic disease (icad) is a high prevalent cause of stroke, especially in asian population and can be categorized as either symptomatic (resulting in acute ischemic stroke) or asymptomatic. treatment for patients who failed with optimal medical therapy (omt) is still elucidating.

in symptomatic ischemic stroke due to intracranial large severe stenosis or occlusive artery, the choice for treatment has remained controversial after results of the stenting versus aggressive medical therapy for intracranial arterial stenosis (sammpris) trial because it demonstrated that the efficacy of medical treatment was superior to intracranial stenting (is) in the low risk of periprocedural stroke or death. however, this conclusion has influenced the role of is in the secondary prevention of ischemic stroke and recovery time for a long time because of the improper patient selection of this trial such as no evidence of medical failure, is in case of moderate intracranial stenosis and is in patients with transient ischemic attacks only. recently, the food and drug administration (fda) mandated study about is, the wingspan stent system post market surveillance (weave) trial, reported not only 97.4% patients with no complication at 72 hours, but also a relatively low 8.5% recurrent stroke and death rate during 1 year in the wingspan one year vascular imaging events and neurologic outcomes (woven) study about wingspan stent (stryker, kalamazoo, mi). in case of the symptomatic stenosis greater than 70%, the probability of recurrent stroke and transient ischemic attack in the territory of the symptomatic stenotic artery in 1 year was 23% and 14%, respectively, despite treatment with antithrombotic therapy and standard management of vascular risk. given a lot of patients with symptomatic ischemic stroke who have some adjustable indications for intracranial stenting deployment with wingspan stent in the world and a paucity of evidence from the comprehensive stroke centers about other self-expanding stents, credo stent (acandis gmbh, pforzheim, germany), our purpose was to compare the periprocedural complication and rate of 1-year recurrent ischemic stroke associating to the is between beyond 7 days from acute stage and the progressive ischemic stroke time.

Eligibility criteria:
inclusion criteria: * evidence of severe intracranial stenosis * target intracranial artery ≥ 2 mm * absence of intracranial hemorrhage * procedure treated with the credo stent (acandis, pforzheim, germany) exclusion criteria: * premorbid modified rankin scale (mrs) score ≥ 2 * intracranial rescue stenting for acute ischemic stroke within 24 hours * loss to follow-up after discharge * systemic lupus erythematosus * more procedures at the same time

Keywords: ischemic stroke intracranial atherosclerosis intracranial stenting
12-week, double-blind, placebo-controlled study of 20 and 60 mg/day istradefylline in parkinson's disease patients on levodopa/carbodopa

Conditions: Parkinson's Disease

Summary: a 12-week, multicenter, double-blind, randomized study designed to evaluate the safety and efficacy of 20 and 60 mg/day istradefylline compared with placebo in subjects with off-time phenomena and advanced parkinson's disease treated with levodopa/carbidopa.


Eligibility criteria:
inclusion criteria: 1. united kingdom parkinson's disease society brain bank diagnostic criteria (steps 1 and 2). 2. modified hoehn and yahr in the off state of ii-iv. 3. treated with levodopa/carbidopa for at least one year with a stable regimen for 4 weeks prior to randomization. 4. taking at least 4 doses of levodopa/carbidopa per day (3 doses if at least 2 doses contained slow-release formulation) with predictable end of dose wearing off. 5. successfully competed parkinson's disease patient diary training with at least 120 minutes of off time per day. 6. stable regimen of other antiparkinson's medications for 4 weeks prior to randomization. 7. at least 30 years of age and able to give written informed consent. exclusion criteria: 1. treatment with liquid levodopa/carbidopa within 4 weeks of randomization. 2. treatment with mao inhibitors except selegiline. 3. treatment within 3 months with centrally acting dopamine antagonists (6 months for depot formulations), e.g., antipsychotic neuroleptics, metoclopramide, buspirone, amoxapine. 4. neurosurgical operation for parkinson's disease. 5. atypical parkinsonism or secondary parkinsonism variants. 6. diagnosis of cancer or evidence of continued disease within 5 years. 7. clinically significant illness of any organ system (e.g., alt or ast \> 1.5 times the upper limit of normal). 8. mini-mental status examination score of 25 or less. 9. history of drug or alcohol abuse or dependence within 2 years. 10. history of psychotic illness or seizures. 11. clinically relevant depression disorder. 12. history of neuroleptic malignant syndrome. 13. pregnancy or lactation. women of child bearing potential must use a reliable method of contraception.

Keywords: parkinson's disease levodopa end of dose wearing off off time
effect of bfr rehab after achilles tendon rupture

Conditions: Achilles Tendon Rupture

Summary: the purpose of this study is to determine if blood flow restriction therapy after achilles tendon rupture reconstruction decreases post-operative calf atrophy, improves reported outcomes, and ultimately decreases return to play time.

the purpose of this research study is to determine if the use of blood flow restriction, bfr, therapy in addition to standard physical therapy (pt) for post-achilles tendon rupture reconstruction will decrease post-operative muscle atrophy (loss of muscle), increases dorsal and planar ankle flexion (range of motion), increase strength, and ultimately decrease return to play time for the bfr therapy group as compared to the control group. participants in this study will be randomly divided into either bfr group that will receive bfr therapy in addition to standard physical therapy protocol post-operatively or the control group which will undergo the standard pt protocol. all participants will complete full body composition scans (dexa) and questionnaires before surgery, prior to physical therapy (three weeks post-op), eight weeks post-op, and 16 weeks post-op. subjective and objective measures will be taken at physical therapy eight weeks and 16 weeks post-operatively.

Eligibility criteria:
inclusion criteria: * achilles rupture confirmed by mri or thompson test * adult * receiving percutaneous achilles repair system (pars) or open repair * proposed pt with methodist location exclusion criteria: * obesity (bmi\>35) * diabetes * cardiovascular, renal, liver or pulmonary disease * active infections * cancer (current or treated within the past 2 years) or coagulation disorder * physically unable to participate in the intervention * unable to complete a minimum of 85% of the assigned rehabilitation sessions * less than 18 years of age * pregnant

Keywords: achilles tendon rupture blood flow restriction
efficiency of muscle energy techniques

Conditions: Mechanical Low Back Pain

Summary: purpose: the aim of this study is to investigate the efficiency of the muscle energy technique in female patients with mechanical low back pain. methods: a total of 40 female participants aged 30-45 were randomly divided into two groups (study group and control group). control group participants were under 10 sessions conventional physical therapy and rehabilitation (tens, us, hot pack) and performed standard home exercises. study group participants were under 8 sessions muscle energy technique in addition to conventional physical therapy and standard home exercises. pain (visual analog scale-vas), spinal mobility (modify schober test-mst), flexibility (fingertip floor distance-ffd, right and left lateral flexion floor distance-lffd), quality of life (nottingham health profile-nhp), disability (oswestry disability index-odi), kinesiofobia (tampa kinesiofobia scale-tks) and depressive symptoms (beck depression inventory-bdi) were measured at baseline, after the treatment and 3th months.

there are many epidemiological and statistical studies showing the high incidence and prevalence of low back pain, which is a common problem all over the world (manga et al 1993). mechanical causes constitute 90% of the factors that cause low back pain (diamond and borenstein 2006). mechanical low back pain (mlbp) is musculoskeletal pain of soft tissue origin that can be seen in the posterior lumbal region, sacral region or paraspinal region. mlbp, which is characterized by tendonitis, trigger points and muscle spasms, increases with movement and decreases with rest. muscle energy technique (met) is a manual therapeutic procedure that creates voluntary contractions in skeletal muscles by creating force against the practitioner by the patient. met is used to lengthen shortened muscles, mobilize restricted joints, and strengthen physiologically weakened muscles (chaitow 2013). treatment methods generally applied to patients diagnosed with mlbp; physical therapy modalities, manual techniques, exercise therapy, medical therapy, psychological therapy and patient education. it is recommended that met be used to reduce pain when administered to the spine (wilson 2003) or muscles (ballantyne et al. 2003). the aim of our study is to investigate the efficiency of muscle energy technique on spinal mobility, flexibility, pain, disability, fear avoidance behavior, quality of life and depressive symptoms in female patients with mechanical low back pain.

Eligibility criteria:
inclusion criteria: * being a volunteer female between the ages of 30 and 45 * having a complaint of low back pain for at least 3 months with the diagnosis of mechanical low back pain exclusion criteria: * having previous spinal surgery * having radicular type low back pain * having neuromuscular disease

Keywords: efficiency mechanical low back pain muscle energy techniques
long-term outcomes of patients treated for bladder exstrophy by questionnaires.

Conditions: Bladder Exstrophy

Summary: the bladder exstrophy epispadias complex (beec) is a rare spectrum of congenital conditions due to abnormal development of the cloacal membrane. of these conditions, bladder exstrophy (be) represent a mild form and requires several complex surgical corrections to gain access to a urinary and fecal acceptable continence and a normal sexual function at adulthood. despite the surgeries, patients may suffer, in the long term, from functional impairments (incontinence, sexuality disorders) which can impact severely their quality of life. however, only a few studies investigate long term issues of bladder exstrophy patients, with heterogenous population and small samples. the department of pediatric surgery of the hospices civils of lyon is an expert center in the management of patients born with bladder exstrophy. at adulthood, departments of adult urology continue the follow-up and treat residual complications. thus, a large cohort of adults and adolescents' patients with bladder exstrophy is currently followed at our institution. therefore, the aim of this study is to evaluate urinary continence, fecal continence, sexuality and quality of life among a large cohort of patients treated for bladder exstrophy, using questionnaires. all patients over 15 years old and treated for bladder exstrophy at our institution are included in the study. exclusion's criteria are : patients treated for epispadias or cloacal exstrophy, patients initially treated of their bladder exstrophy abroad with no access to the surgical report, patients under a guardianship measure. all included patients are contacted by e-mail or phone to answer the questionnaire. the purpose of statistical analysis is to evaluate the average score in each field of investigation: * mean iciq score for urinary continence * mean flqi score for fecal continence * mean fsfi score for sexuality in women * mean iief-5 score for sexuality in men * mean sf-12 score for quality of life, in comparison of mean sf-12 score in general french population based on literature secondary objectives are to assess the impact of different surgical strategies used for bladder exstrophy reparation on urinary continence, fecal continence, sexuality and quality of life ; to describe the population from a sociological point of view (level of study, profession, marital status) and to describe the population reproductive status (pregnancy, delivery modalities, paternity and maternity status, use of medically assisted procreation).


Eligibility criteria:
inclusion criteria: * patients born with bladder exstrophy or cloacal exstrophy * aged 15 and over at time of enrolment * treated at the hospices civils of lyon exclusion criteria: * patients treated for epispadias * patients initially treated of their bladder exstrophy abroad with no access to the surgical report * patients under a guardianship measure * deceased patients

Keywords: bladder exstrophy quality of life urinary continence fecal continence
registry of covid-19 patients at aoui verona

Conditions: Coronavirus Disease 2019

Summary: the registry of covid-19 patients was designed to collect epidemiolgical, demographic, clinical, anamnestic and outcome information together with serological and microbiological samples from covid-19 patients admitted at the university hospital of verona (azienda ospedaliera universitaria integrata, aoui verona). all sars-cov 2 positive patients admitted and able to give an informed consent are included, irrespectively of age and gender.

anamnestic data are collected at the enrollment, while all the other clinical and epidemiological information are retrieved retrospectively from patients' medical records and electronic health records. serological and microbiological samples (blood samples, fecal samples and nasal/rectal swabs) are collected within 48 hours after admission and during the hospital stay, according with routine internal procedures.the biological samples are stored at the university laboratory for medical research (laboratorio universitario di ricerca medica, lurm). a dedicated database has been created and implemented to collect all the above mentioned information.

Eligibility criteria:
inclusion criteria: * pcr for sars-cov 2 positive on nps swab or high suspicion of sars-cov 2 with ongoing swab; * all ages; * all genders; * informed consent obtained. exclusion criteria: * failure to obtain the informed consent.
periapical healing after one or two-visits to endodontic treatment in adolescents patients

Conditions: Periapical Periodontitis

Summary: the main objective of this study is the prevention and repair of apical periodontitis in lower molars with pulp necrosis after the execution of endodontic treatment in one or two visits in adolescent patients. moreover, it is also observed the frequency of postoperative pain in endodontic treatment.

this project is developed in adolescent patients who have need of endodontic treatment in necrotic molars. the patients were randomly divided into two groups of treatment: one and two visits. the treatment protocol is the same for both groups, except the number of visits and the use of intra canal medication in the group treated in two visits. patients will be followed clinically and radiographically for a minimum period of two years. the data was collected by the evaluation of postoperative pain and to determine the healing of periapical lesions, characterizing the success of the treatment.

Eligibility criteria:
inclusion criteria: 1. patients healthy 2. not have taken analgesic, anti-inflammatory or antibiotic drugs during the 10 days prior to the beginning of treatment 3. lower first or second permanent molars with complete root formation and dental pulp necrosis with or without symptoms exclusion criteria: 1. presence of periodontal diseases 2. pulp calcification 3. acute dent-alveolar abscesses 4. hemorrhage in the canal after access

Keywords: periapical periodontitis dental pulp necrosis root canal therapy adolescent
hfnc and acute hypercapnic respiratory failure

Conditions: High Flow Oxygen Therapy; Acute Hypercapnic Respiratory Failure; COPD Exacerbation

Summary: high-flow nasal cannula (hfnc) enables delivering humidified gas at high-flow rates controlling the oxygen inspired fraction (fio2). its efficacy has been demonstrated in hypoxemic acute respiratory failure. however, little is known about its use in hypercapnic acute respiratory failure (arf). therefore, we aimed to evaluate the effect of using hfnc through "precision flow" equipment as first line of ventilatory support for copd patients with hypercapnic acute respiratory failure.


Eligibility criteria:
inclusion criteria: * moderate to very severe copd patients (gold 2 to 4) over 18 years old admitted to the icu with hypercapnic arf (paco2\> 45 mmhg and respiratory acidosis \[ph ≥7.30\], with or without hypoxemia + one of the following: respiratory rate ≥25 cycles per minute, intercostal and / or supraclavicular recruitment, or thoraco-abdominal synchrony, no prior use of niv) exclusion criteria: * patients less than 18 years old * mild copd patients * absence of hypercapnia * kelly m score \> 3 * haemodynamic instability (despite fluid resuscitation) * niv or invasive mechanical ventilation (imv) (need to use previously to hfnc) * contraindications to implement high-flow oxygen therapy.
alrex® versus patanol in the treatment of seasonal allergic conjunctivitis(sac)

Conditions: Seasonal Allergic Conjunctivitis

Summary: this study is to evaluate the safety and efficacy of alrex (le ophthalmic suspension, 0.2%) versus patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis (sac).


Eligibility criteria:
inclusion criteria: * subjects who are diagnosed with acute sac and experience at least grade 4 ocular itching and at least grade 2 bulbar conjunctival injection (redness) in each eye due to seasonal allergy at visit 1. exclusion criteria: * subjects who have a known hypersensitivity to the study medications or their components or contraindications to ocular corticosteroids. * subjects who use any of the disallowed medications throughout the duration of the study and during the period indicated prior to visit 1. * subjects who have intraocular pressure (iop) greater than 21 mm hg in either eye or any type of glaucoma. * subjects who have a history of any severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study or affect the subject's safety or trial parameters.

Keywords: ocular allergy